Intercept's OCA drug linked with worsened cholesterol levels


Patients who received Intercept Pharmaceuticals' (ICPT) beticholic acid (OCA) for the treatment of NASH in a trial for the chronic liver disease experienced increased bad cholesterol and lower good cholesterol, the NIH said after the close on Friday in a statement to the WSJ.

The NIH said it was releasing the information to give "broader context" to its earlier findings that OCA showed a "highly statistically significant improvement" in measures of liver health vs. those who received a placebo

Intercept didn't mention cholesterol abnormalities in two statements it put out on Thursday, nor in a subsequent analyst call. While the NIH told Intercept earlier in the week that patients had experienced "lipid effects," it failed to furnish Intercept with details. "We had no concrete data with respect to lipids," CEO Mark Pruzanski said.

Pruzanski told the WSJ that previous studies have shown that OCA can raise lipid levels, and it was already "very public" that OCA "impacts lipid metabolism."

Intercept's shares skyrocketed 516% on Thursday and Friday to $445.83 following news of the early ending of the study.

From other sites
Comments (8)
  • PChan444
    , contributor
    Comments (514) | Send Message
     
    my friend tried OCA at a party and he got AIDS from it
    12 Jan 2014, 11:03 AM Reply Like
  • musicmaker
    , contributor
    Comments (503) | Send Message
     
    could be a lot of fine print here... +570% in a couple days might have been a bit too far, too fast
    12 Jan 2014, 11:05 AM Reply Like
  • Tack
    , contributor
    Comments (16182) | Send Message
     
    Now, there's an understatement.
    12 Jan 2014, 11:45 PM Reply Like
  • ilex cramer
    , contributor
    Comments (2) | Send Message
     
    One word ...CRESTOR
    12 Jan 2014, 11:58 PM Reply Like
  • jakewarren
    , contributor
    Comment (1) | Send Message
     
    So, what will happen with Bank Of America's target price of $872 for ICPT stocks? This seems like it will shoot back down..
    12 Jan 2014, 11:59 PM Reply Like
  • Harel
    , contributor
    Comments (23) | Send Message
     
    Hi',
    I posted some time ago the reason why to
    take the analysts with more than a pinch of salt.
    Another proof of this preposition .
    Anyhow, the down correction is quite imminent.

     

    13 Jan 2014, 11:24 AM Reply Like
  • Holthusen
    , contributor
    Comments (700) | Send Message
     
    While laying in a Hospital Bed with a failing Liver, I'm sure the patient is very worried about his "good" and "bad" cholesterol levels!
    13 Jan 2014, 11:07 AM Reply Like
  • Chance Burton
    , contributor
    Comments (7) | Send Message
     
    One of a lot of its kind in this Market, look for others to bite the dust.
    13 Jan 2014, 02:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs